Biosynex SA (ALBIO.PA)

EUR 1.35

(-12.65%)

Market Cap (In EUR)

14.57 Million

Revenue (In EUR)

92.97 Million

Net Income (In EUR)

-36.94 Million

Avg. Volume

17.79 Thousand

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.28-8.97
PE
-
EPS
-
Beta Value
-2.078
ISIN
FR0011005933
CUSIP
F1151J107
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Larry Abensur
Employee Count
-
Website
https://www.biosynex.com
Ipo Date
2011-03-28
Details
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company offers a range of rapid diagnostic tests, immunoblots, molecular biology, and point of care products for screening, diagnosis, and prevention in the areas of bacteriology, parasitology, mycology, virology, biochemistry and oncology, and women's health, as well as COVID-19 tests and instruments. It also provides self-tests; self-measurement products, including thermometers and blood pressure monitors; and oral care and medical aid products. The company provides its products to biology and medical analysis laboratories, hospitals, pharmacies, hyper and supermarkets, etc. It also exports its products internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France.